Hardik Chandasana
Overview
Explore the profile of Hardik Chandasana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chandasana H, Buchanan A, McKenna M, Brothers C, Hyatt S, Adkison K, et al.
J Clin Pharmacol
. 2024 Sep;
PMID: 39235061
In March 2022, the US Food and Drug Administration expanded indications of TRIUMEQ, a once-daily fixed-dose combination (FDC) containing abacavir (ABC), dolutegravir (DTG), and lamivudine (3TC) to include pediatric patients...
2.
Buchanan A, Bekker A, Chandasana H, DeMasi R, Lulic Z, Ernest T, et al.
Int J Antimicrob Agents
. 2024 Aug;
64(4):107306.
PMID: 39146996
The HIV treatment landscape for adults has progressed dramatically in recent decades; however, paediatric populations continue to experience delayed and limited access to effective and safe antiretroviral therapy options. Despite...
3.
Chandasana H, Bush M, Vavro C, Huang J, Ait-Khaled M, Wynne B, et al.
Clin Pharmacol Ther
. 2024 Jul;
116(4):1100-1109.
PMID: 39014548
Dolutegravir (DTG) is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and...
4.
Chandasana H, Bush M, Ait-Khaled M, Wynne B, Min S, Mehta R
J Clin Pharmacol
. 2024 Jul;
64(11):1407-1418.
PMID: 39011960
The World Health Organization has recommended the use of dolutegravir (DTG) for both first and second-line antiretroviral treatment in both adults and children down to 4 weeks of age. We...
5.
Chandasana H, van Dijkman S, Mehta R, Bush M, Rabie H, Flynn P, et al.
Infect Dis Ther
. 2024 Jul;
13(8):1877-1891.
PMID: 38961048
Introduction: Once-daily fixed-dose combinations (FDC) containing abacavir (ABC), dolutegravir (DTG), and lamivudine (3TC) have been approved in the US for adults and children with HIV weighing ≥ 6 kg. This...
6.
Yu Y, Dooley F, Woods A, Gunnett A, Chandasana H, Amini E, et al.
J Clin Med
. 2024 Jun;
13(12).
PMID: 38930053
Cefazolin may minimize the risk of surgical site infection (SSI) following posterior spinal fusion (PSF) for adolescent idiopathic scoliosis (AIS). Cefazolin dosing recommendations vary and there is limited evidence for...
7.
Chandasana H, Hayes S, Buchanan A, Brothers C, Wiznia A, Bartlett M, et al.
AIDS
. 2024 May;
38(9):F11-F18.
PMID: 38768443
Objective: Dolutegravir (DTG) is a once-daily HIV-1 integrase inhibitor approved for the treatment of HIV-1 infection in adults and children from 4 weeks of age. The posology of DTG in...
8.
Chandasana H, Singh R, Adkison K, Ait-Khaled M, Pene Dumitrescu T
Antimicrob Agents Chemother
. 2024 Apr;
68(5):e0150423.
PMID: 38587380
A fixed-dose combination (FDC) of 50 mg dolutegravir and 300 mg lamivudine is indicated for the treatment of HIV-1 infection. This analysis aimed to characterize the population pharmacokinetics (PK) of...
9.
Chandasana H, Thapar M, Hayes S, Baker M, Gibb D, Turkova A, et al.
Clin Pharmacokinet
. 2023 Aug;
62(10):1445-1459.
PMID: 37603217
Background And Objective: HIV treatment options remain limited in children. Dolutegravir is a potent and well-tolerated, once-daily HIV-1 integrase inhibitor recommended for HIV-1 infection in both adults and children down...
10.
Brooks K, Kiser J, Ziemba L, Ward S, Rani Y, Cressey T, et al.
Lancet HIV
. 2023 Aug;
10(8):e506-e517.
PMID: 37541705
Background: Child-friendly fixed-dose combination (FDC) antiretroviral therapy (ART) options are limited. We evaluated the pharmacokinetics, safety, and tolerability of dispersible and immediate-release FDC abacavir, dolutegravir, and lamivudine taken once per...